红细胞改造作为药物载体研究进展
Advances in Reformed Erythrocytes as Drug Deliver System
DOI: 10.12677/NAT.2021.113005, PDF,    科研立项经费支持
作者: 陈 超, 冯灵子, 李 佳, 鲍鸿一, 夏栋林：南通大学公共卫生学院，江苏 南通
关键词: 药物递送体系；红细胞；纳米颗粒；细胞膜修饰； Drug Delivery System； Erythrocyte； Nanopar-ticles； Reformed Membrane
摘要: 红细胞作为人体循环系统内数目最多的细胞，具有生物安全性高、免疫源性低、柔韧性强、系统循环长、药物负载量高等特点，可解决当前传统药物输送体系面临的许多挑战性问题，故而被广泛研究。目前红细胞修饰作为药物递送载体已形成了多种成熟、可行的方法，主要可分为：基因修饰的红细胞载体、非基因修饰的红细胞载体和红细胞膜修饰纳米颗粒。本文综述了红细胞作为纳米药物载体的概况及研究进展，总结了红细胞改造的研究成果，并展望了红细胞药物递送系统的发展趋势。
Abstract: Erythrocytes, the most abundant cell type in the human body, are high bio-safety, hypoimmunogenic, flexibility, long cycling, and high drug loading. It was extensively studied as it can overcome many challenges in current conventional drug delivery systems. Up to now, there are many mature and feasible methods in reforming erythrocytes as drug carriers, which are mainly divided into the gene modification of erythrocytes, non-gene modification of erythrocytes and erythrocyte membrane modification of nano particles. This review focuses on the latest research progress on the reformed erythrocytes as drug nanocarriers. We also summarized the primary findings of reformed erythrocytes and outlooked future developing trends in reformed erythrocytes drug delivery system.
文章引用：陈超, 冯灵子, 李佳, 鲍鸿一, 夏栋林. 红细胞改造作为药物载体研究进展[J]. 纳米技术, 2021, 11(3): 36-42. https://doi.org/10.12677/NAT.2021.113005

参考文献

[1] Wu, S.H., Hsieh, C.C., Hsu, S.C., et al. (2021) RBC-Derived Vesicles as a Systemic Delivery System of Doxorubicin for Lysosomal-Mitochondrial Axis-Improved Cancer Therapy. Journal of Advanced Research, 30, 185-196. [Google Scholar] [CrossRef] [PubMed]
[2] Kim, M.W., Lee, G., Niidome, T., et al. (2020) Platelet-Like Gold Nanostars for Cancer Therapy: The Ability to Treat Cancer and Evade Immune Reactions. Frontiers in Bioengineering and Biotechnology, 8, 133. [Google Scholar] [CrossRef] [PubMed]
[3] Wang, Y., Zhou, C., Ding, Y., et al. (2021) Red Blood Cell-Hitchhiking Chitosan Nanoparticles for Prolonged Blood Circulation Time of Vitamin K1. International Journal of Pharmaceutics, 592, Article ID: 120084. [Google Scholar] [CrossRef] [PubMed]
[4] Rossi, L., Pierigè, F., Antonelli, A., et al. (2016) Engineering Erythrocytes for the Modulation of Drugs’ and Contrasting Agents’ Pharmacokinetics and Biodistribution. Advanced Drug Delivery Reviews, 106, 73-87. [Google Scholar] [CrossRef] [PubMed]
[5] Singh, M.P., Flynn, N.H., Sethuraman, S.N., et al. (2021) Repro-gramming the Rapid Clearance of Thrombolytics by Nanoparticle Encapsulation and Anchoring to Circulating Red Blood Cells. The Journal of Controlled Release, 329, 148-161. [Google Scholar] [CrossRef] [PubMed]
[6] Tan, S., Wu, T., Zhang, D., et al. (2019) Cell or Cell Membrane-Based Drug Delivery Systems. Theranostics, 5, 863-863. [Google Scholar] [CrossRef] [PubMed]
[7] Zelepukin, I.V., Yaremenko, A.V., Shipunova, V.O., et al. (2019) Nano-particle-Based Drug Delivery via RBC-Hitchhiking for the Inhibition of Lung Metastases Growth. Nanoscale, 11, 1636-1646. [Google Scholar] [CrossRef] 
[8] Li, C., Wang, X., Li, R., et al. (2019) Resveratrol-Loaded PLGA Nanoparticles Functionalized with Red Blood Cell Membranes as a Biomimetic Delivery System for Prolonged Circulation Time. Journal of Drug Delivery Science and Technology, 54, Article ID: 101369. [Google Scholar] [CrossRef] 
[9] Luk, B.T. and Zhang, L. (2015) Cell Membrane-Camouflaged Nanoparticles for Drug Delivery. Journal of Controlled Release, 220, 600-607. [Google Scholar] [CrossRef] [PubMed]
[10] Maeder, M.L. and Gersbach, C.A. (2016) Genome-Editing Technologies for Gene and Cell Therapy. Molecular Therapy, 24, 430-446. [Google Scholar] [CrossRef] [PubMed]
[11] Huang, N.J., Pishesha, N., Mukherjee, J., et al. (2017) Genetically Engi-neered Red Cells Expressing Single Domain Camelid Antibodies Confer Long-Term Protection against Botulinum Neu-rotoxin. Nature Communications, 8, 423. [Google Scholar] [CrossRef] [PubMed]
[12] 杨根生, 金陈浩, 徐书敏, 等. 红细胞药物递送系统的研究进展[J]. 浙江工业大学学报, 2020, 48(6): 684-689.
[13] Sun, X., Wang, C., Gao, M., et al. (2015) Remotely Con-trolled Red Blood Cell Carriers for Cancer Targeting and Near-Infrared Light-Triggered Drug Release in Combined Pho-tothermal-Chemotherapy. Advanced Functional Materials, 25, 2386-2394. [Google Scholar] [CrossRef] 
[14] Xu, Q., Wan, J., Bie, N., et al. (2018) A Biomimetic Gold Nanocag-es-Based Nanoplatform for Efficient Tumor Ablation and Reduced Inflammation. Theranostics, 8, 5362-5362. [Google Scholar] [CrossRef] [PubMed]
[15] Villa, C.H., Anselmo, A.C., Mitragotri, S., et al. (2016) Red Blood Cells: Supercarriers for Drugs, Biologicals, and Nanoparticles and Inspiration for Advanced Delivery Systems. Advanced Drug Delivery Reviews, 106, 88-103. [Google Scholar] [CrossRef] [PubMed]
[16] Zhu, R., Avsievich, T., Popov, A., et al. (2021) In Vivo Nano-Biosensing Element of Red Blood Cell-Mediated Delivery. Biosensors and Bioelectronics, 175, Article ID: 112845. [Google Scholar] [CrossRef] [PubMed]
[17] Mai, T.D., d’Orlyé, F., Ménager, C., et al. (2013) Red Blood Cells Decorated with Functionalized Core-Shell Magnetic Nanoparticles: Elucidation of the Adsorption Mechanism. Chemical Communications, 49, 5393-5395. [Google Scholar] [CrossRef] [PubMed]
[18] Zhao, Y., Sun, X., Zhang, G., et al. (2011) Interaction of Mesoporous Silica Nanoparticles with Human Red Blood Cell Membranes: Size and Surface Effects. ACS Nano, 5, 1366-1375. [Google Scholar] [CrossRef] [PubMed]
[19] Chambers, E. and Mitragotri, S. (2007) Long Circulating Nanoparticles via Adhesion on Red Blood Cells: Mechanism and Extended Circulation. Experimental Biology and Medicine, 232, 958-966.
[20] 李诗浩, 张麟. 红细胞膜封装负载姜黄素的金纳米粒子[J]. 精细化工, 2020, 37(9): 97-102.
[21] Sun, X., Han, X., Xu, L., et al. (2017) Surface-Engineering of Red Blood Cells as Artificial Antigen Pre-senting Cells Promising for Cancer Immunotherapy. Small, 13, Article ID: 1701864. [Google Scholar] [CrossRef] [PubMed]
[22] Wang, C., Ye, Y., Sun, W., et al. (2017) Red Blood Cells for Glu-cose-Responsive Insulin Delivery. Advanced Materials, 29, Article ID: 1606617. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, F.Y., Zhuang, J., Esteban, F., Ávila, B., et al. (2019) A Na-nomotor-Based Active Delivery System for Intracellular Oxygen Transport. ACS Nano, 13, 11996-12005. [Google Scholar] [CrossRef] [PubMed]
[24] Gao, M., Liang, C., Song, X., et al. (2017) Erythro-cyte-Membrane-Enveloped Perfluorocarbon as Nanoscale Artificial Red Blood Cells to Relieve Tumor Hypoxia and En-hance Cancer Radiotherapy. Advanced Materials, 29, Article ID: 1701429. [Google Scholar] [CrossRef] [PubMed]
[25] Fang, R.H., Hu, C.M.J., Chen, K.N.H., et al. (2013) Lipid-Insertion Enables Targeting Functionalization of Erythrocyte Membrane-Cloaked Nanoparticle. Nanoscale, 5, 8884-8888. [Google Scholar] [CrossRef] [PubMed]
[26] Rao, L., Meng, Q.F., Bu, L.L., et al. (2017) Erythrocyte Mem-brane-Coated Upconversion Nanoparticles with Minimal Protein Adsorption for Enhanced Tumor Imaging. ACS Applied Materials & Interfaces, 9, 2159-2168. [Google Scholar] [CrossRef] [PubMed]
[27] Li, S.H. and Zhang, L. (2020) Erythrocyte Membrane Nano-Capsules: Biomimetic Delivery and Controlled Release of Photothermal-Photochemical Coupling Agents for Cancer Cell Therapy. Dalton Transactions, 49, 2645-2651. [Google Scholar] [CrossRef] 
[28] Wang, S., Yin, Y.P.C., Song, W., et al. (2020) Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging-Guided Cancer Photothermal Therapy. Journal of Materials Chemistry B, 8, 803-812. [Google Scholar] [CrossRef] 
[29] Malhotra, S., Dumoga, S., Sirohi, P., et al. (2019) Red Blood Cells-Derived Vesicles for Delivery of Lipophilic Drug Camptothecin. ACS Applied Materials & Interfaces, 11, 22141-22151. [Google Scholar] [CrossRef] [PubMed]
[30] Gu, F., Zhang, L., Teply, B.A., et al. (2008) Precise Engineering of Targeted Nanoparticles by Using Self-Assembled Biointegrated Block Copolymers. Proceedings of the National Academy of Sciences of the United States of America, 105, 2586-2591. [Google Scholar] [CrossRef] [PubMed]
[31] Pridgen, E.M., Alexis, F., Kuo, T.T., et al. (2013) Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal fc Receptor for Oral Delivery. Science Translational Medicine, 5, 213ra167. [Google Scholar] [CrossRef] [PubMed]
[32] 万胜利, 杨刚, 叶云. 新型载体及新技术在治疗酶研究中的应用[J]. 中国生物医学工程学报, 2020(1): 114-118.
[33] Phan, A., Takimoto, C., Adinin, R., et al. (2017) Open La-bel Phase I Study of MBP-426, a Novel Formulation of Oxaliplatin, in Patients with Advanced or Metastatic Solid Tu-mors. Molecular Cancer Therapeutics, 6, 3563S-3564S.
[34] Davis, M.E., Zuckerman, J.E., Choi, C.H.J., et al. (2010) Evidence of RNAi in Humans from Systemically Administered siRNA via Targeted Nanoparticles. Nature, 464, 1067-1070. [Google Scholar] [CrossRef] [PubMed]
[35] Pierigè, F., Bigini, N., Rossi, L., et al. (2017) Reengineering Red Blood Cells for Cellular Therapeutics and Diagnostics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobi-otechnology, 9, e1454. [Google Scholar] [CrossRef] [PubMed]
[36] Gao, W. and Zhang, L. (2015) Engineering Red-Blood-Cell-Membrane-Coated Nanoparticles for Broad Biomedical Applications. AIChE Journal, 61, 738-746. [Google Scholar] [CrossRef] 
[37] Shi, J., Kantoff, P.W., Wooster, R., et al. (2017) Cancer Nanomedicine: Progress, Challenges and Opportunities. Nature Reviews Cancer, 17, 20-21. [Google Scholar] [CrossRef] [PubMed]
[38] He, H., Ye, J., Wang, Y., et al. (2014) Cell-Penetrating Peptides Medi-tated Encapsulation of Protein Therapeutics into Intact Red Blood Cells and Its Application. Journal of Controlled Re-lease, 176, 123-132. [Google Scholar] [CrossRef] [PubMed]

为你推荐